KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Shares Issued (2017 - 2025)

Alnylam Pharmaceuticals' Shares Issued history spans 17 years, with the latest figure at $41.7 million for Q4 2025.

  • For Q4 2025, Shares Issued rose 14.95% year-over-year to $41.7 million; the TTM value through Dec 2025 reached $250.0 million, down 17.47%, while the annual FY2025 figure was $250.0 million, 17.47% down from the prior year.
  • Shares Issued reached $41.7 million in Q4 2025 per ALNY's latest filing, down from $77.7 million in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $153.0 million in Q3 2022 to a low of $22.5 million in Q2 2022.
  • Average Shares Issued over 5 years is $60.3 million, with a median of $48.2 million recorded in 2021.
  • Peak YoY movement for Shares Issued: crashed 83.79% in 2023, then surged 335.54% in 2024.
  • A 5-year view of Shares Issued shows it stood at $45.0 million in 2021, then increased by 25.92% to $56.7 million in 2022, then crashed by 45.53% to $30.9 million in 2023, then rose by 17.43% to $36.3 million in 2024, then grew by 14.95% to $41.7 million in 2025.
  • Per Business Quant, the three most recent readings for ALNY's Shares Issued are $41.7 million (Q4 2025), $77.7 million (Q3 2025), and $81.2 million (Q2 2025).